Xiamen Amoytop Biotech Co., Ltd.

Shanghai Stock Exchange 688278.SS

Xiamen Amoytop Biotech Co., Ltd. Total Assets for the year ending December 31, 2023: USD 331.85 M

Xiamen Amoytop Biotech Co., Ltd. Total Assets is USD 331.85 M for the year ending December 31, 2023, a 29.49% change year over year. Total assets are the total value of all assets owned by a company, representing its resources.

Xiamen Amoytop Biotech Co., Ltd. Total Assets for the year ending December 31, 2022 was USD 256.28 M, a 14.34% change year over year.
Xiamen Amoytop Biotech Co., Ltd. Total Assets for the year ending December 31, 2021 was USD 224.14 M, a 22.66% change year over year.
Xiamen Amoytop Biotech Co., Ltd. Total Assets for the year ending December 31, 2020 was USD 182.73 M, a 61.11% change year over year.
Xiamen Amoytop Biotech Co., Ltd. Total Assets for the year ending December 31, 2019 was USD 113.42 M, a 10.21% change year over year.

Key data

Date	Total Assets	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity

Shanghai Stock Exchange: 688278.SS

Xiamen Amoytop Biotech Co., Ltd.

CEO	Mr. Li Sun
IPO Date	Jan. 17, 2020
Location	China
Headquarters	No. 330 Wengjiao Road
Employees	1,960
Sector	Healthcare
Industries Biotechnology Chemicals & Advanced Materials Cleaning Supplies Composite Materials Fertilizers Petrochemicals Pharmaceuticals Plastics

Description

Xiamen Amoytop Biotech Co., Ltd. engages in the manufacture, marketing, and sale of recombinant protein drugs using genetic engineering technology in China. It offers formulations, reagents, and APIs, as well as custom-manufacturing services. The company was founded in 1996 and is based in Xiamen, China.

Key trends

Past 5 years